Solti

Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

Prudence A. Francis, Meredith M. Regan, Gini F. Fleming et al. · New England Journal of Medicine · 2014 · 727 citations · Full text

Medicine, Gynecology, Oncology +16

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy

Debora Fumagalli, David Venet, Michail Ignatiadis et al. · JAMA Oncology · 2016 · 157 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

Aleix Prat, Valentina Guarneri, Tomás Pascual et al. · EBioMedicine · 2022 · 145 citations · Full text

Medicine, Bioinformatics, Oncology +17

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Miguel Martín, Christoph Zielinski, Manuel Ruíz‐Borrego et al. · Annals of Oncology · 2020 · 133 citations · Full text

Medicine, Oncology, Pharmacology +15

Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis

Susana García‐Recio, Toshinori Hinoue, Gregory Wheeler et al. · Nature Cancer · 2022 · 114 citations · Full text

Medicine, Molecular Biology, Oncology +17